Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 Pipeline Review 2016 - Research and Markets

Research and Markets
Posted on: 28 Sep 16

Research and Markets has announced the addition of the "A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016" report to their offering.

A disintegrin and metalloproteinase with thrombospondin motifs 5 or ADAMTS5 is an enzyme encoded by the ADAMTS5 gene. It plays an important role in the destruction of aggrecan in arthritic diseases and in proteolytic processing mostly during the peri-implantation period.

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively.

Our latest report A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2016, outlays comprehensive information on the A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 Overview
  3. Therapeutics Development
  4. Pipeline Products for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Overview
  5. Pipeline Products for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Comparative Analysis
  6. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Therapeutics under Development by Companies
  7. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Therapeutics under Investigation by Universities/Institutes
  8. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Products under Development by Companies
  13. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Products under Investigation by Universities/Institutes
  14. A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Companies Involved in Therapeutics Development
  • Asahi Kasei Pharma Corp.
  • GlaxoSmithKline Plc
  • Oscotec Inc.
  • Paradigm Biopharmaceuticals Limited

For more information about this report visit http://www.researchandmarkets.com/research/mrrsc8/a_disintegrin_and

View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005734/en/

Business Wire
www.businesswire.com

Last updated on: 28/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.